Aptamer-gold nanozyme based competitive lateral flow assay for rapid detection of CA125 in human serum.
Aptamer
CA125
Lateral flow assay
Nanozyme
Journal
Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
received:
02
04
2020
revised:
27
05
2020
accepted:
05
06
2020
pubmed:
31
7
2020
medline:
15
5
2021
entrez:
31
7
2020
Statut:
ppublish
Résumé
For several decades, point-of-care technology (POCT) has proven its potential regarding swift and cost-efficient detection of analytes. Lateral flow assay is a highly popular POC technology that needs improvisation to increase its sensitivity, cost effectiveness and quantification so that it becomes more user friendly and affordable technology. In this context, the present study has investigated the use of aptamers and nanozymes together for the first time in developing an Aptamer-nanozyme lateral flow assay (ALFA). The present study uses a specific aptamer for CA125 as capture reagent and peroxidase mimetic gold nanoparticles as label for detection of CA125 in human serum through developed competitive ALFA. The assay was specific and has a limit of detection of 3.71 U/mL. The ALFA test was in house validated for its precision, recovery and showed a significant correlation with established CA125 chemiluminiscent ELISA with P-value<0.0001. In summary, this assay quantitatively detects an analyte by using an aptamer and peroxidase mimetic gold nanoparticles that ensures circumventing the use of antibodies and incorporating enzyme mimetic activity in assay systems.
Identifiants
pubmed: 32729500
pii: S0956-5663(20)30362-6
doi: 10.1016/j.bios.2020.112368
pii:
doi:
Substances chimiques
Aptamers, Nucleotide
0
Gold
7440-57-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112368Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.